secwatch.observer — SEC 8-K summary
======================================

Issuer:     SOLENO THERAPEUTICS INC (SLNO)
CIK:        0001484565
Form:       8-K
Filed at:   2023-09-29T23:59:59+00:00
Accession:  0001193125-23-247533
Event type: other_material
Sentiment:  neutral
Materiality: 0.75
Item codes: 1.01, 3.02, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Soleno prices $120M combined public offering and private placement of common stock and pre-funded warrants
--------------------------------------------------------------------------------

- Public offering of 3M shares at $20/share, gross ~$60M; underwriter option exercised for 450k additional shares.
- Concurrent private placement of 1.825M shares and 1.175M pre-funded warrants at $20/share equivalent; total ~$60M.
- Combined gross proceeds ~$120M; net to Soleno ~$64.5M from offering; expected close Oct 2, 2023.
- Proceeds to advance lead candidate DCCR for Prader-Willi syndrome through late-stage development and regulatory approval.
- Lead underwriters: Guggenheim, Cantor Fitzgerald, Oppenheimer; Laidlaw as lead manager.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1484565/000119312523247533/0001193125-23-247533-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1484565/000119312523247533/d331815d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-23-247533

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer